Analysts at Wedbush initiated coverage on shares of Telix Pharmaceuticals Limited American Depositary Shares (NASDAQ:TLX - Get Free Report) in a research note issued on Thursday, Marketbeat Ratings reports. The brokerage set an "outperform" rating and a $22.00 price target on the stock. Wedbush's price objective would suggest a potential upside of 31.19% from the stock's previous close.
Separately, William Blair reissued an "outperform" rating on shares of Telix Pharmaceuticals Limited American Depositary Shares in a research note on Wednesday, March 12th.
Check Out Our Latest Research Report on TLX
Telix Pharmaceuticals Limited American Depositary Shares Price Performance
NASDAQ TLX traded down $0.59 during mid-day trading on Thursday, reaching $16.77. 12,873 shares of the company's stock traded hands, compared to its average volume of 26,048. The company has a fifty day simple moving average of $16.76 and a 200-day simple moving average of $16.87. Telix Pharmaceuticals Limited American Depositary Shares has a 1-year low of $13.61 and a 1-year high of $30.36.
Institutional Investors Weigh In On Telix Pharmaceuticals Limited American Depositary Shares
An institutional investor recently bought a new position in Telix Pharmaceuticals Limited American Depositary Shares stock. ABC Arbitrage SA purchased a new stake in Telix Pharmaceuticals Limited American Depositary Shares (NASDAQ:TLX - Free Report) during the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 26,939 shares of the company's stock, valued at approximately $451,000.
Telix Pharmaceuticals Limited American Depositary Shares Company Profile
(
Get Free Report)
Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals.
Further Reading
Before you consider Telix Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Telix Pharmaceuticals wasn't on the list.
While Telix Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
